PixarBio (PixarBio) Debt-to-Revenue : 0.00 (As of Sep. 2016)

View and export this data going back to 2016. Start your Free Trial

What is PixarBio Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

PixarBio's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2016 was $0.00 Mil. PixarBio's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2016 was $0.00 Mil. PixarBio's annualized Revenue for the quarter that ended in Sep. 2016 was $0.06 Mil. PixarBio's annualized Debt-to-Revenue for the quarter that ended in Sep. 2016 was 0.00.

PixarBio Debt-to-Revenue Historical Data

The historical data trend for PixarBio's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PixarBio Debt-to-Revenue Chart

PixarBio Annual Data

Trend

Dec14

Dec15

Debt-to-Revenue

PixarBio Quarterly Data
	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16
Debt-to-Revenue	Get a 7-Day Free Trial					-	-	-	-	-

Competitive Comparison of PixarBio's Debt-to-Revenue

For the Biotechnology subindustry, PixarBio's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PixarBio's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PixarBio's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where PixarBio's Debt-to-Revenue falls into.

PixarBio Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

PixarBio's Debt-to-Revenue for the fiscal year that ended in Dec. 2015 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(0	+	0)	/	0.1
	=	0.00

PixarBio's annualized Debt-to-Revenue for the quarter that ended in Sep. 2016 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(0	+	0)	/	0.06
	=	0.00

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Sep. 2016) Revenue data.

PixarBio Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of PixarBio's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

PixarBio (PixarBio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PixarBio Corp (GREY:PXRB) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

200 Boston Avenue, Suite 1875, Medford, MA, USA, 02155

Website

https://www.pixarbio.com

PixarBio Corp is a specialty pharmaceutical company focused on preclinical and clinical commercial development of therapeutic drug delivery systems for post-operative pain. The company's lead clinical candidate, NeuroRelease is a non-opioid / non-opiate preclinical stage product intended for the treatment of surgical pain, with planned future indications for chronic pain. NeuroRelease blocks nociceptive and neuropathic pain signals arising from temperature and pressure stimuli without affecting motor function, which is intended to allow for effective treatment without delaying post-surgical physical therapy.